sodium (Z)-2-(methoxycarbonyl)-3-phenylpropan-2-ene-1-sulfonate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: sodium (Z)-2-(methoxycarbonyl)-3-phenylpropan-2-ene-1-sulfonate
• 英文别名: (Z)-2-Carbomethoxy-3-phenyl-2-propene-1-sulfonic Acid Sodium Salt；sodium;(Z)-2-methoxycarbonyl-3-phenylprop-2-ene-1-sulfonate
• 化学式: C₁₁H₁₁O₅S*Na
• 分子量: 278.261
• InChiKey: UHBLENXLIAOSGX-HCUGZAAXSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.21
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  91.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  sodium (Z)-2-(methoxycarbonyl)-3-phenylpropan-2-ene-1-sulfonate 在 镍 五氯化磷 、 氢气 作用下， 以 甲苯 为溶剂， 生成 methyl 2-Benzyl-3-(4-methyl-piperazin-1-ylsulfonyl)propionate
  参考文献：
  名称：

  Enzyme-catalyzed synthesis of optically Pure β-sulfonamidopropionic acids. Useful starting materials for P-3 site modified renin inhibitors.

  摘要：

  The novel and efficient preparation of several racemic beta-sulfonamidopropionate esters is described. Treatment of the racemic esters with Chymotrypsin or Subtilisin Carlsberg (purified or detergent grade) provided the corresponding (S)-carboxylic acids in 60-90% yield. These acids (75 to >98 % e.e.) are useful starting materials for the synthesis of P-3 site modified renin inhibitors.

  DOI：

  10.1016/0040-4039(93)85095-e
• 作为产物：
  描述：

  (Z)-methyl 2-(bromomethyl)-3-phenylacrylate 在 sodium sulfite 作用下， 以 甲醇 、 水 为溶剂， 生成 sodium (Z)-2-(methoxycarbonyl)-3-phenylpropan-2-ene-1-sulfonate
  参考文献：
  名称：

  Enzyme-catalyzed synthesis of optically Pure β-sulfonamidopropionic acids. Useful starting materials for P-3 site modified renin inhibitors.

  摘要：

  The novel and efficient preparation of several racemic beta-sulfonamidopropionate esters is described. Treatment of the racemic esters with Chymotrypsin or Subtilisin Carlsberg (purified or detergent grade) provided the corresponding (S)-carboxylic acids in 60-90% yield. These acids (75 to >98 % e.e.) are useful starting materials for the synthesis of P-3 site modified renin inhibitors.

  DOI：

  10.1016/0040-4039(93)85095-e

文献信息

• Peptidyl difluorodiol renin inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0416393A1

  公开（公告）日：1991-03-13

  A renin inhibiting compound of the formula: wherein A is a functional group; W is (1) -C(O)-, (2) -CH(OH)- or (3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl; U is (1) -C(O)-, (2) -CH₂- or (3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-; V is (1) -CH-, (2) -C(OH)- or (3) -C(halogen)- with the proviso that v is -CH-­when U is -N(R₂)-; Q is -CH(R₁)- or -C(=CHR1a)- wherein R₁ is (1) loweralkyl, (2) cycloalkylalkyl, (3) arylalkyl, (4) (heterocyclic)alkyl, (5) 1-benzyloxyethyl, (6) phenoxy, (7) thiophenoxy or (8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R₃ is a functional group; R₄ is (1) loweralkyl, (2) cycloalkylmethyl or (3) benzyl; R₅ is -CH(OH)- or -C(O)-; R₆ is -CH(OH)- or -C(O)-; and Z is (1) lower alkyl, (2) aryl, (3) arylalkyl, (4) cycloalkyl, (5) cycloalkylalkyl, (6) heterocyclic or (7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一种肾素抑制化合物的化学式：其中A是一个功能基团；W是(1) -C(O)-，(2) -CH(OH)-或(3) -N(R₂)-，其中R₂是氢或较低烷基；U是(1) -C(O)-，(2) -CH₂-或(3) -N(R₂)-，其中R₂是氢或较低烷基，但当W为-CH(OH)-时，则U为-CH₂-，并且当U为-N(R₂)-时，U为-C(O)-或-CH₂-；V是(1) -CH-，(2) -C(OH)-或(3) -C(卤素)-，但当U为-N(R₂)-时，V为-CH-；Q是-CH(R₁)-或-C(=CHR1a)-，其中R₁是(1) 较低烷基，(2) 环烷基烷基，(3) 芳基烷基，(4) (杂环)烷基，(5) 1-苄氧乙基，(6) 苯氧基，(7) 噻吩氧基或(8) 氨基苯基，前提是当R₁是苯氧基、噻吩氧基或氨基苯基时，B是-CH₂-或-CH(OH)-，或A是氢，而R1a是芳基或杂环；R₃是一个功能基团；R₄是(1) 较低烷基，(2) 环烷基甲基或(3) 苄基；R₅是-CH(OH)-或-C(O)-；R₆是-CH(OH)-或-C(O)-；Z是(1) 较低烷基，(2) 芳基，(3) 芳基烷基，(4) 环烷基，(5) 环烷基烷基，(6) 杂环或(7) (杂环)烷基；或其药学上可接受的盐、酯或前药。
• Psoriasis treatment
  申请人：Abbott Laboratories

  公开号：US05122514A1

  公开（公告）日：1992-06-16

  The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for treatment of psoriasis.

  本发明涉及利用肾素抑制剂和肾素抑制剂组合物治疗牛皮癣。
• Encapsulated renin inhibitor composition
  申请人：Abbott Laboratories

  公开号：US05178877A1

  公开（公告）日：1993-01-12

  A pharmaceutical composition comprising a solution of a tenin inhibitor of the formula: ##STR1## wherein R.sub.1 is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl; R.sub.2 is benzyl, p-methoxybenzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl; R.sub.3 is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH.sub.3 S-- or CH.sub.3 SCH.sub.2 --; R.sub.4 is loweralkyl or cyclopropyl; R.sub.5 is hydrogen or loweralkyl; and X is CH.sub.2 or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof in a pharmaceutically acceptable solvent, said solution being encapsulated in a soft elastic gelatin capsule.

  一种包含下列式中的十二烷基酮酸酯的溶液的制药组合物：其中R.sub.1是4-哌嗪基、1-甲基-4-哌嗪基、1-甲基-1-氧代-4-哌嗪基、2-氧代-4-哌嗪基、4-吗啉基、4-硫代吗啉基或1-甲基-4-异哌嗪基；R.sub.2是苄基、对甲氧基苄基、2-苯基乙基、1-萘甲基或2-萘甲基；R.sub.3是4-噻唑基、2-氨基-4-噻唑基、2-噻唑基、5-噻唑基、1-吡唑基、3-吡唑基、1-咪唑基、正丙基、异丙基、CH.sub.3 S-或CH.sub.3 SCH.sub.2-；R.sub.4是较低烷基或环丙基；R.sub.5是氢或较低烷基；X是CH.sub.2或NH；或其药理学上可接受的盐、酯或前药在药理学上可接受的溶剂中的溶液，所述溶液被封装在一种软弹性明胶胶囊中。
• Method for treating renal disease
  申请人：Abbott Laboratories

  公开号：US05182266A1

  公开（公告）日：1993-01-26

  The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for prevention, treatment, inhibition or reversal of renal dysfunction or disease, especially renal failure.

  本发明涉及使用肾素抑制剂和肾素抑制剂组合物预防、治疗、抑制或逆转肾功能障碍或疾病，特别是肾衰竭。
• Process for the preparation of a renin inhibiting compound
  申请人：Abbott Laboratories

  公开号：US05275950A1

  公开（公告）日：1994-01-04

  Intermediates and a process for their preparation are disclosed which are useful for the preparation of a renin inhibiting compound of the formula: ##STR1## wherein R is a nitrogen-containing heterocycle which is bonded via a nitrogen atom to the sulfonyl group, R.sub.6 is hydrogen, alkoxy, halogen or loweralkyl, R.sub.7 is loweralkyl having 2 to 7 carbon atoms, and R.sub.8 is loweralkyl, cycloalkyl, or aryl or a pharmaceutically acceptable acid addition salt thereof.

  本发明公开了一种中间体及其制备方法，可用于制备一种抑制肾素的化合物，其化学式为：##STR1## 其中R是通过氮原子与磺酰基结合的含氮杂环，R.sub.6是氢、烷氧基、卤素或低烷基，R.sub.7是具有2至7个碳原子的低烷基，R.sub.8是低烷基、环烷基或芳基，或其药学上可接受的酸加成盐。